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Shaheen E. Lakhan1*, Christopher T. Ford1,2 and Deborah Tepper3Abstract
Background: Members of the family Zingiberaceae including turmeric, ginger, Javanese ginger, and galangal have
been used for centuries in traditional medicine. Preclinical studies of Zingiberaceae extracts have shown analgesic
properties. This study aims to systematically review and meta-analyze whether extracts from Zingiberaceae are
clinically effective hypoalgesic agents.
Methods: Literature was screened from electronic databases using the key words Zingiberaceae AND pain OR visual
analogue score (VAS) to identify randomized trials. From this search, 18 studies were identified, and of these, 8
randomized, double-blinded, placebo-controlled trials were found that measured pain by VAS for inclusion in the
meta-analysis.
Results: Findings indicated significant efficacy of Zingiberaceae extracts in reducing subjective chronic pain (SMD − 0.67;
95 % CI − 1.13 to − 0.21; P = 0.004). A linear dose-effect relationship was apparent between studies (R2 = 0.71). All studies
included in the systematic review reported a good safety profile for extracts, without the renal risks associated with
non-steroidal anti-inflammatory drugs, and with similar effectiveness.
Conclusion: Our findings indicated that Zingiberaceae extracts are clinically effective hypoalgesic agents and the
available data show a better safety profile than non-steroidal anti-inflammatory drugs. However, both non-steroidal
anti-inflammatory drugs and Zingiberaceae have been associated with a heightened bleeding risk, and there have been
no comparator trials of this risk. Further clinical studies are recommended to identify the most effective type of
Zingiberaceae extract and rigorously compare safety, including bleeding risk.
Keywords: VAS, Ginger, Turmeric, Galangal, Curcumin, CurcumaBackground
Turmeric (Curcuma longa), ginger (Zingiber officinale),
Javanese ginger (Curcuma zanthorrhiza), and galangal
(Alpinia galanga), which are members of the family Zin-
giberaceae, have been used for centuries in traditional
medicine [1, 2]. Zingiberaceae have received scientific
interest as dietary anti-inflammatory agents [3, 4], and
pilot human trials have indicated benefits for chronic
diseases including osteoarthritis, rheumatoid arthritis,
and major depressive disorder [5–7]. Commonly pre-
scribed medications for pain, principally non-steroidal
anti-inflammatory drugs (NSAIDs), have side effects
with long-term use [8], leading to calls for safer tools for
the management of chronic pain [9].* Correspondence: slakhan@gnif.org
1Global Neuroscience Initiative Foundation, Los Angeles, California, USA
Full list of author information is available at the end of the article
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unless otherwise stated.Turmeric’s principal bioactive is the polyphenol curcu-
min [10], which can be extracted using organic solvents
[11]. Curcumin has anti-inflammatory properties [12]; its
mechanisms include down-regulation of nuclear factor
(NF)-κB [13] and cyclooxygenase 2 (Cox-2) [14]. Animal
studies have shown antinociceptive effects of oral curcu-
min [15] and indicated the involvement of ATP-sensitive
potassium channels [16]. Pilot human studies of curcumin
have shown promise for improving symptoms of rheuma-
toid arthritis and inflammatory bowel disease [5, 17]. Cur-
cumin is poorly bioavailable and it is likely that its benefits
are mediated via secondary metabolites [18].
The primary anti-inflammatory components of ginger
are gingerol and zingerone [3, 19]; however, other ginger
components also have anti-inflammatory activities
in vivo [20]. Mechanisms of action include modulation
of leukotriene and prostaglandin synthesis, and inhibition. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Lakhan et al. Nutrition Journal  (2015) 14:50 Page 2 of 10of NF-κB [3, 19, 21]. One meta-analysis was previously
conducted on ginger for pain, but the authors concluded
too few rigorous studies were available at that time to
make a confident recommendation [22].
Galangal polyphenols were shown to protect against
lipopolysaccharide-induced injury in a rodent model, in-
dicating a functional anti-inflammatory effect in vivo
[23, 24]. In vitro work has suggested that the galangal
component 1′-acetoxychavicol modulates a transient re-
ceptor potential (TRP) cation channel [25]. Javanese gin-
ger contains curcumin [26] and zanthorrhizol, which is
also a Cox-2 inhibitor [27]. Javanese ginger extract and
zanthorrhizol have anti-inflammatory effects in vivo [28]
and Javanese ginger extract displayed anti-nociceptive
effects in mice [29].
Preclinical studies of Zingiberaceae extracts have shown
antinociceptive effects [29–32]. Previous reviews have
considered Zingiberaceae species for particular clinical sit-
uations [33, 34], but no prior reviews have examined all
Zingiberaceae for chronic pain. The present review and
meta-analysis aims to include randomized controlled trials
(RCTs) that have used Zingiberaceae extracts for a condi-
tion involving chronic pain. Since the time window for ab-
sorption and action of Zingiberaceae extracts is unknown,
but is probably less than 24 h based on data for other
herbal extracts [35], we only included studies involving
treatment periods lasting 24 h or longer. While chronic
pain is typically defined as pain present for at least
3 months, for this meta-analysis we included pain present
for greater than 24 h to capture a sufficient number of
studies of non-acute pain.
The aim of this systematic review and meta-analysis is to
assess the potential for hypoalgesic effects of Zingiberaceae
extracts in conditions involving chronic pain.
Methods
Literature search strategy
The meta-analysis was conducted according to Cochrane
and PRISMA guidelines [36]. Published studies were identi-
fied by searching PubMed, ScienceDirect, and Cochrane Li-
brary databases, using the following search terms, which
include the common and taxonomic names of the Zingiber-
aceae species, and specific bioactive components found in
each plant: turmeric, curcumin, ginger, galangal, Zingibera-
ceae, Curcuma, Zingiber, Kaempferia, Alpinia, curcumi-
noid, turmerone, gingerol, shogaol, zingiberene, zingiberol,
zingerone, curcumene, galangin, zanthorrhizol, AND pain
OR visual analogue score OR VAS. The references within
each identified report were manually reviewed. Publications
were included that were published before December 2014.
Selection of studies for inclusion in the systematic review
Studies were included in the systematic review if they
met the following criteria: a) the study was randomized;b) the study included a patient group with chronic pain,
i.e., pain lasting 24 h or longer; c) extracts from one or
more Zingiberaceae species were given either alone or in
combination with agents intended to increase the bio-
availability of the Zingiberaceae bioactives, but not to-
gether with other treatments or non-Zingiberaceae
herbal extracts; d) Zingiberaceae extracts were given for
24 h or longer, and e) pain was measured as a study out-
come. Papers were excluded before review stage if they
were not peer-reviewed, full-length, original research re-
ports (for example they were reviews, editorials, confer-
ence abstracts, etc.)
Selection of studies for inclusion in the meta-analysis
Further selection criteria were applied for inclusion of
papers into the meta-analysis. Papers were excluded
from the meta-analysis that were: a) not placebo-
controlled; b) not double-blinded; or c) did not measure
pain using VAS.
Data extraction
Group sample sizes, and means and standard deviations
for pain, were extracted from each included report for
pooled analysis. To focus the meta-analysis and
maximize the accuracy of comparisons between studies,
we chose to only extract and analyze data for the VAS
measurement of pain. Other measurements varied
widely between the included papers, which investigated
divergent patient groups. Where studies involved more
than one treatment group, data was only extracted for
the group treated with the Zingiberaceae extract in its
least processed and/or highest dose form. For studies
reporting results for multiple time points, data were ex-
tracted for the longest treatment time period, except in
the study by Black et al. [37], where, because pain in the
placebo group decreased over time after the eccentric
exercise protocol, the earliest time point of 24 h supple-
mentation was selected.
Data analysis
The standardized mean difference (SMD) was calculated
allowing for a continuous pain rating scale such as the
VAS. The SMD is a useful statistical tool when studies
all assess the same outcome but measure it in a variety
of ways. Effect sizes for all included studies were calculated
and weighted by variance. In accordance with Higgins
et al., 2003 [38], heterogeneity was considered to be low at
I2 ≤ 25 %, moderate at I2 ≤ 50 %, high at I2 ≤ 75 %, and very
high at I2 > 75 %. All calculations were performed using
the StatsDirect software package, version 2.7.9. P-values
were considered significant at ≤0.05. The potential for
publication bias was assessed using the funnel plot
method [39]. A symmetric funnel plot indicates that there
was little bias based on the sample size of the analyzed
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meta-analysis may be flawed because of inappropriate
weight given to small versus large studies. We have no
specific reason to suspect bias in this research area. Since
the included studies for quantitative analysis used a wide
range of Zingiberaceae extract doses, a post-hoc decision
was made to draw a dose-effect curve for SMDs against
mg of extract/day used in each study.
Results
We screened 43 unique records and rejected 25 of these
because either they were not controlled or they investi-
gated pain lasting for less than 24 h. The systematic re-
view included 18 randomized trials for qualitative
analysis and the meta-analysis included 8 RCTs (Fig. 1).
Those 10 RCTs that were included in the qualitative syn-
thesis, but not the quantitative analysis, were excluded
from the meta-analysis either because they were not
double-blinded, or they were not placebo-controlled, or
they measured pain by a method other than VAS.
Systematic review
Chronic pain has traditionally been described as pain
present for 12 weeks or longer, although this definition
has been shifting to include a less rigid time frame.
Chronic pain as defined by the International Association
for the Study of Pain (IASP) as “pain that persists be-
yond normal tissue healing time”. This meta-analysis uti-
lized a broad definition of chronic pain to include painFig. 1 PRISMA flow chart showing the numbers of identified,
screened, included, and excluded studies for the systematic review
(qualitative synthesis) and meta-analysis (quantitative analysis)greater than 24 h in order to capture a meaningful num-
ber of studies.
Chronic pain is a symptom of many long-term medical
conditions, including cancer, arthritis, nerve damage
after traumatic injury, and neuropathy associated with
chronic conditions such as diabetes. It has serious ad-
verse effects on multiple dimensions of quality of life
[40]. In Europe, 19 % of adults were found to experience
chronic pain of moderate to severe intensity in a survey
published in 2006, and of the survey respondents, 40 %
felt that management of their pain was inadequate [41].
Side effects of currently prescribed treatments for
chronic pain have led to calls for the development of
new and safer approaches [8]. This systematic review ex-
plores randomized human trials of Zingiberaceae ex-
tracts for chronic pain, defined for this meta-analysis as
pain lasting for longer than 24 h.
Chronic pain in arthritic conditions
The first randomized trial of Zingiberaceae extracts that
measured pain as an outcome investigated the effects of
510 mg of ginger extract/day for osteoarthritis using a
crossover, double-blinded, placebo-controlled study de-
sign. The ginger-treated group reported significantly less
pain compared with the placebo group for the first
period before crossover, but not after crossover, while
the ibuprofen group showed a stronger reduction in pain
[42]. Shortly thereafter, another double-blinded, random-
ized, placebo-controlled trial was conducted for osteo-
arthritis, again with a treatment dose of 510 mg/day, but
using a mixed Zingiberaceae treatment comprising gin-
ger and galangal extracts. A moderate reduction of pain
on walking was detected after 6 weeks of treatment,
compared with the placebo group [43]. A 6-month,
placebo-controlled study in symptomatic gonarthritis
(knee arthritis) patients investigated the effects of a
higher dose of 1000 mg/day of ginger extract with cross-
over between ginger and placebo groups at 3 months. In
the second period after crossover, significantly less pain
was reported in the ginger group, compared with the
placebo group [44]. Ginger extract was used in a further
study for osteoarthritis at 340 mg/day dosage, and was
found to be equally as effective as diclofenac for pain re-
lief, but with a superior safety profile, indicated by sig-
nificantly fewer adverse gastropathic changes in the
ginger group, compared with the diclofenac group [45].
A trial of curcumin for knee osteoarthritis, in which pa-
tients took 1000 mg curcumin/day as an adjuvant to
diclofenac treatment, found no significant difference be-
tween the curcumin + diclofenac group and the placebo
+ diclofenac group [46]. An open-label comparative trial
treated patients with knee osteoarthritis using diclofenac
+ placebo, ginger extract (1500 mg/day) + placebo, or
diclofenac + ginger. The results showed that all three
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12 weeks of treatment than at baseline, and the diclofe-
nac plus ginger group reported significantly less pain
than the diclofenac + placebo and ginger + placebo treat-
ment groups [47]. Another trial in knee osteoarthritis,
investigating the effects of supplementation with
1000 mg/day of turmeric extract, found significantly less
pain in the treatment group compared with the placebo
group [48]. A trial comparing 1500 mg/day of turmeric
extract with ibuprofen for knee osteoarthritis concluded
that turmeric extract and ibuprofen were equally effect-
ive in reducing pain [49]. In a different study, treatment
with 1500 mg/day of curcuminoids was found to signifi-
cantly reduce pain in knee osteoarthritis compared with
a placebo group [50]. In summary, there have been mul-
tiple randomized trials of Zingiberaceae extracts for
arthritis (osteoarthritis and gonarthritis), which have
mostly found moderate reductions in reported subjective
pain, with Zingiberaceae extracts showing comparable
effectiveness to standard NSAID treatments. The evi-
dence for turmeric extracts/curcumin for chronic pain
in osteoarthritis is stronger than that for ginger extracts.
Pain in primary dysmenorrhea
A trial of ginger extract for primary dysmenorrhea found
that 1000 mg of ginger extract/day resulted in a reduc-
tion of pain with equal effectiveness to each of two
NSAID control groups (mefenamic acid and ibuprofen)
[51]. A placebo-controlled trial was conducted, with pa-
tients taking 1500 mg of ginger extract/day. Significant
reductions in the severity and duration of pain were de-
tected in the ginger-treated group, compared with the
placebo group [52]. Although only two randomized
studies were available, their findings suggest that ginger
extract may be an effective treatment for pain in primary
dysmenorrhea.
Pain in delayed onset muscle soreness
Volunteers who performed a strenuous eccentric exer-
cise protocol (18 eccentric extensions of the elbow flexor
muscles against resistance at 120 % of their concentric
one-repetition maximum) and were treated with either
raw or heat-treated ginger extracts at 2000 mg/day dos-
age reported less pain associated with delayed onset
muscle soreness than a placebo group [36]. A similar
study was performed using a high-bioavailability curcu-
min formulation, with 400 mg/day curcumin given to
volunteers who underwent a milder eccentric exercise
protocol (downhill running on a treadmill for 45 min).
This study also found a reduction in pain for the treated
group, compared with the placebo group, however this
difference was significant only for the muscles of the an-
terior thigh [53]. These studies suggest that Zingibera-
ceae extracts may have a moderate hypoalgesic effect fordelayed onset muscle soreness following eccentric exer-
cise. Further trials are recommended to determine the
most effective extract type and dose.
Pain in recovery from surgery
A double-blinded, placebo controlled trial of high-dose
curcumin (2000 mg/day) for patients recovering from
laparoscopic cholecystectomy found a significant reduc-
tion in pain at weeks 1 and 3 of treatment in the treated
group, compared with the placebo group [54]. The re-
sults of this single study suggest curcumin may alleviate
pain following surgery.
Chronic pain in irritable bowel syndrome
A pilot study of turmeric extract for irritable bowel syn-
drome (IBS), which had two dose groups, both with rela-
tively low intake (72 and 144 mg/day, respectively),
found a modest but significant reduction in abdominal
pain for both the lower- and higher-dose turmeric ex-
tract treatment groups [55]. Another trial investigated
Javanese ginger extract for IBS, with patients taking
60 mg of extract/day for 18 weeks in a double-blinded,
placebo-controlled study. In this trial, no significant dif-
ference in pain was found between the treatment and
placebo groups [56]. In light of findings for Zingibera-
ceae extracts for other conditions, we recommend fur-
ther trials in IBS using higher treatment doses.
Pain in cancer radiotherapy-induced dermatitis
A double-blinded, placebo controlled trial of breast can-
cer patients undergoing radiotherapy investigated the ef-
fects of very high-dose curcumin (6000 mg/day) on pain
associated with radiation dermatitis. Although significant
improvement was seen for some other radiation derma-
titis symptoms with curcumin treatment, no significant
difference was seen for pain scores between the
curcumin-treated and placebo groups [57]. Based on this
single study, curcumin cannot be recommended as a
pain management tool for radiation dermatitis.
Meta-analysis
The studies that were determined to be eligible for in-
clusion in the quantitative analysis included five studies
using ginger extracts, two studies using curcuminoids or
curcumin, and one study using Javanese ginger extract.
The patient groups included four groups with arthritis
(osteoarthritis or gonarthritis), one group with IBS, one
group with primary dysmenorrhea, one group recovering
from surgery, and one group with muscle soreness fol-
lowing eccentric exercise. All studies included adult par-
ticipants at least 18 years of age. Table 1 lists the
methods and results of each included study, organized
by date of publication. In all included studies, the major-
ity of subjects were female, and in one study, all of the
Table 1 Characteristics of included studies for meta-analysis
Study Patient group Number of
subjects
Percent female Mean age ± SD (years) Intervention Control Results for pain









Capsules containing 170 mg
ginger extract, 3 capsules per
day for 3 weeks.
Placebo (crossover
design).
Pain was not significantly different






124 123 60 63 64.0 ± 11.5 66.3 ± 11.6 Capsules containing 255 mg of
mixed ginger and galangal
rhizome extracts, 2 capsules per
day for 6 weeks.
Placebo (parallel
design).
Pain on walking was significantly
lower in the ginger/galangal group
after 6 weeks of treatment compared









Capsules containing 250 mg
ginger rhizome extract, 4
capsules per day for 3 months.
Placebo (crossover
design).
Pain was significantly lower in the






24 58 58 62 49.5 ± 14.5 49.0 ± 9.1 Capsules containing 20 mg
Javanese ginger extract, 3
capsules per day for 18 weeks.
Placebo (parallel
design).
Pain was not significantly different






20 20 65 65 20.6 ± 0.6 21.4 ± 0.8 Capsules containing 333 mg
ginger rhizome extract, 6




Pain was significantly lower in the






25 25 84 80 38.4 ± 12.8 37.2 ± 12.7 Capsules containing 500 mg




Pain was significantly lower in the






59 46 100 100 21.4 ± 2.0 21.3 ± 2.2 Capsules containing 500 mg
ginger rhizome powder, 3
capsules per day for 5 days.
Placebo (parallel
design).
Pain was significantly lower in the






19 21 73 81 57.32 ± 8.78 57.57 ± 9.05 Capsules containing 500 mg
curcuminoids and 5 mg black
pepper extract (bioavailability




Pain was significantly more reduced
in the curcuminoid treatment group,
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imply bias in sampling or selection, it can also be inter-
preted as being due to the known higher risk of females
for arthritis [58], IBS [59], and gallstones necessitating
laparoscopic cholecystectomy [60].
Publication bias
Following the methods of Egger et al., 1997 [39], a fun-
nel plot was drawn for standard error against effect size
(Fig. 2) to assess the possibility of publication bias, for
example, the selective reporting of trials showing posi-
tive results, but not those producing negative results in
the literature. The funnel plot was not fully symmetrical,
which is an indicator for possible bias, but bias could
not be concluded due to lack of statistical significance
(Egger’s test, P = 0.10; a P-value less than 0.05 would
demonstrate significant bias). In addition, inconsistency
between studies was very high (I2 = 87.5 %), a factor that
can contribute to asymmetry in funnel plots without ne-
cessarily implying bias.
Meta-analysis of Zingiberaceae extracts for pain
One of the inclusion criteria by which the 8 RCTs of
Zingiberaceae extracts included in the meta-analysis
were selected was that they all used the same measure-
ment tool (VAS) for the assessment of pain. A random-
effects meta-analysis was performed according to the
methods of DerSimonian and Laird, 1986 [61] (Fig. 3).
This was necessary because of the heterogeneity of ef-
fects in the included studies. This analysis decreased the
heterogeneity and allows for meaningful therapeutic
findings. The standardized mean difference (SMD) for
pain was large (−0.67, 95 % CI: −1.13 to −0.21), withFig. 2 A funnel plot for pain, showing standard error plotted against effect size
The plot was not completely symmetrical, indicating potential bias, but bias co
P = 0.10). A high degree of inconsistency between studies (I2 = 87.5) may contrsignificantly lower reported subjective pain in the experi-
mental group compared with the control group (P = 0.004).
Heterogeneity between studies was very high (I2 = 87.5 %).
SMDs and confidence intervals for studies included in the
meta-analysis are shown in Table 2.
Dose-dependent effect of Zingiberaceae extracts for pain
To determine whether the reduction in subjective pain
by turmeric showed a dose-effect relationship across the
7 studies included in the quantitative meta-analysis, a
scatter plot was drawn between the SMD for each study
and the total dose of Zingiberaceae extract taken by sub-
jects per day (Fig. 4). The results suggested a linear
dose-effect relationship (R2 = 0.71).
Discussion
Compared with placebo controls, an overall moderate to
large effect of Zingiberaceae extracts (including turmeric,
ginger, and Javanese ginger) was found for reported
chronic pain. While there was substantial heterogen-
eity between studies in their effect sizes, this may
partly be explained by the wide variability in the doses
of Zingiberaceae extracts used in each study. A dose-
response curve was plotted and revealed a strong dose-
effect relationship.
No previous meta-analyses have considered all Zingi-
beraceae for chronic pain, but one prior analysis was
conducted on ginger extracts only. The conclusion of
that study was that there were insufficient studies on
ginger at that time to make any recommendation on the
effectiveness of ginger extracts for pain [22]. Meta-
analyses have been conducted on Zingiberaceae extracts
for several other parameters. A meta-analysis of curcumin(SMD). Each data point represents one RCT included in the meta-analysis.
uld not be concluded due to a lack of statistical significance (Egger’s test,
ibute to the asymmetry of the funnel plot
Fig. 3 Random-effects meta-analysis Forest plot showing standardized mean differences (SMDs) for each study of Zingiberaceae extracts included
in the quantitative analysis, sorted by date of publication. The meta-analysis findings indicated that Zingiberaceae extracts significantly reduced
subjective pain (P = 0.004; SMD -0.67; 95 % CI -1.13 to -0.21). Earlier studies tended to use lower doses, which may explain the tendency for more
recent studies to have larger effect sizes. Each study is represented by a square, with the area of the square corresponding to the weight given
to that study in the meta analysis (weighting based on the number of subjects in each trial). The estimated overall effect size is displayed as a
diamond. Horizontal lines show 95 % confidence intervals
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[62]. A meta-analysis of ginger extracts for chemotherapy-
induced nausea and vomiting did not identify any signifi-
cant benefit compared with placebo [63], but two other
meta-analyses of ginger for the treatment of nausea and
vomiting induced by pregnancy [64] and during post-
operative recovery [65], respectively, found significantTable 2 Effect sizes (SMDs) and confidence intervals for each study
included in the meta-analysis. Negative SMDs show a reduction
of pain in the treatment group for that study compared with
the placebo control group






56 56 −0.05 −0.42 −0.32
Altman et al.
2001 [43]
124 123 −0.16 −0.41 0.09
Wigler et al.
2003 [44]
29 29 −0.46 −0.98 0.07
Brinkhaus et al.
2005 [56]
24 58 0.23 −0.24 0.71
Black et al.
2010 [37]
20 20 −0.69 −1.33 −0.05
Agarwal et al.
2011 [54]
25 25 −1.73 −2.38 −1.08
Rahnama et al.
2012 [52]
59 46 −1.19 −1.61 −0.77
Panahi et al.
2014 [50]
19 21 −1.65 −2.37 −0.93improvement of symptoms by ginger extract treatment
compared with placebo controls.
Our results indicate that Zingiberaceae extracts may
be a useful tool for clinical pain management. However,
certain side effects have been reported that may limit
the use of Zingiberaceae extracts for specific patient
groups. Allergic reaction to Zingiberaceae extracts oc-
curs rarely [66]. Rodent studies have indicated the po-
tential for Zingiberaceae extracts to cause hepatotoxicity
[67], and so their use is cautioned in patients withFig. 4 A scatter plot showing the effect size (standardized mean
difference (SMD), y-axis) for each study included in the meta-analysis,
plotted against the dose of Zingiberaceae extract that was used in
that study (x-axis). The results show that studies using larger doses
of Zingiberaceae extracts tended to report more effective hypoalgesia
(R2 = 0.71). Different markers represent the extract type: Triangle =
Javanese ginger; Circle = Ginger; Square = Mixed ginger and
galangal; Diamond = Curcuminoids/curcumin
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tracts have been reported to have anticoagulant activities
[68] and may potentially exacerbate clotting disorders
[69]. Nausea (usually mild) is a reported potential effect
of Zingiberaceae extracts; however, Drozdov et al., 2012
[46] reported a superior gastropathic safety profile for
ginger extract compared with diclofenac treatment in
osteoarthritis patients. The study included in our sys-
tematic review that used the highest dose, with patients
taking 6000 mg/day of curcumin for 4-7 weeks, reported
no significant adverse events and no significant increase
in gastropathy (diarrhea) in the curcumin group com-
pared with the placebo group [57].
Study limitations
This meta-analysis has several limitations. One is the in-
clusion of only a small number of studies (8 RCTs); al-
though those studies that were included met very
rigorous criteria, all of the included studies were ran-
domized, double-blinded, placebo-controlled, and each
used the same measurement tool (VAS) to quantify sub-
jective pain. Another limitation is that the included stud-
ies showed very high heterogeneity. This variability is,
however, likely to be at least partly due to the strong
dose-effect relationship that we identified and the wide
range of doses used among the studies under analysis
(60-2000 mg of extract/day). The study of different Zin-
giberaceae species and patient populations in each trial
may also contribute to the heterogeneity. The number of
included studies was too small to perform subgroup ana-
lysis. A final limitation is that the included studies
showed a strong gender skew towards female subjects.
Further study in male populations would help to confirm
whether Zingiberaceae extracts offer uniform pain relief
across genders, although there is no clear biological rea-
son to suspect any difference between genders in the re-
sponse to Zingiberaceae extracts.
Although the studies included in the meta-analysis did
not report significant adverse events from Zingiberaceae
treatment, there are indications that caution needs to be
exercised in recommending treatment without further
studies. Zingiberaceae extracts are generally regarded as
safe in lower dosages of concentrated extracts [18, 69].
At higher dosages, there may be an increased risk of
bleeding secondary to impairment of the clotting cas-
cade or platelet dysfunction [68, 70], although this risk is
not well defined. Turmeric supplementation has been
associated with oxalate kidney stones [71]. A toxicology
analysis of curcumin and its derivatives showed there
can be a hepatotoxic effect that is dose-related [72]. Gin-
ger and turmeric have an antiplatelet effect, and coup-
ling either of them with NSAIDs can increase the risk of
significant bleeding [73]. The degree to which these sup-
plements may increase bleeding risk is not well known,however it is recommended that they be stopped two
weeks prior to any surgery or significant dental proced-
ure [74].
Conclusions
Chronic pain is a symptom of numerous medical disor-
ders that may severely reduce quality of life, and its
management is a core requirement of clinical care.
Drugs commonly used for the relief of chronic pain have
side effects that may interdict their use. Our results
show that Zingiberaceae rhizome extracts, which have a
good record of safety in human studies, offer effective
relief from chronic pain. The dose-dependent effect
identified implies that higher doses may potentially in-
crease the effect further. The caveat to these findings is
that they are based on a relatively small number of RCTs
(8 studies), though these studies were included accord-
ing to rigorous criteria. Long term and larger safety
studies of these supplements, particularly at higher
doses, are suggested. In summary, the available evidence
suggests that Zingiberaceae extracts have hypoalgesic ef-
fects for chronic pain. We recommend further study of
high-dose Zingiberaceae extracts for chronic pain manage-
ment in clinical practice, and we also encourage focused as-
sessment to determine the most effective Zingiberaceae
species, extract doses, and bioactive chemicals; such re-
search may potentially facilitate the development of
higher potency hypoalgesic agents based on Zingibera-
ceae bioactives.
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